Stockscreener 앱 받기
9.00
7.27%
0.61
시장 영업 전:
9.80
0.80
+8.89%
전일 마감가:
$8.39
열려 있는:
$8.92
하루 거래량:
1.15M
Relative Volume:
4.10
시가총액:
$188.40M
수익:
-
순이익/손실:
$-52.07M
주가수익비율:
-43.33
EPS:
-0.2077
순현금흐름:
$-44.93M
1주 성능:
+14.80%
1개월 성능:
+13.07%
6개월 성능:
+2.04%
1년 성능:
-10.63%
1일 변동 폭
$8.75
$9.83
1주일 범위
$7.88
$9.83
52주 변동 폭
$4.81
$13.88
Cybin Inc Stock (CYBN) Company Profile
명칭
Cybin Inc
전화
908 764 8385
주소
100 King Street West, Suite 5600, Toronto
CYBN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
9.00 | 188.40M | 0 | -52.07M | -44.93M | -0.2077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 개시 | Guggenheim | Buy |
| 2021-11-19 | 다운그레이드 | Maxim Group | Buy → Hold |
Cybin Inc 주식(CYBN)의 최신 뉴스
Cybin CEO Doug Drysdale: Revolutionizing Depression Treatment - worth.com
Psychedelic Industry Summit: Top CEOs and Investors Unite to Shape $Billion Market Future - Stock Titan
Cybin Provides Corporate Update and Highlights Positive Regulato - GuruFocus
# Cybin begins phase 3 trials for depression treatment CYB003 By Investing.com - Investing.com South Africa
Silicon Valley - FinancialContent
Cybin Advances Phase 3 Program Amid Positive Regulatory Signals - TipRanks
# Cybin begins phase 3 trials for depression treatment CYB003 - Investing.com Australia
Cybin Provides Corporate Update, Highlights Positive Regulatory Signals For Psychedelic Therapeutics - MarketScreener
Should You Buy Polkadot While It's Under $5? - The Globe and Mail
Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics - Business Wire
Prediction: This Company Will Be the Most Valuable AI Stock in 2026 - The Globe and Mail
Billionaire Bill Ackman Just Scooped Up Shares of This Unstoppable Stock - The Globe and Mail
Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Per - GuruFocus
Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference | CYBN Stock News - GuruFocus
Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference - The Globe and Mail
Cybin to Participate in the 2025 Psychedelic Science Conference - GuruFocus
Cybin to Participate in the 2025 Psychedelic Science Conference | CYBN Stock News - GuruFocus
Crypto's hottest new trend: publicly traded companies buying bunches of bitcoin - The Globe and Mail
(CYBN) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Cybin, Inc: The Strategic Approach to Formulating a Successful CYB003 Launch - Smartkarma
Cybin (CYBN) Gains Positive Outlook from Lucid Capital | CYBN St - GuruFocus
Market Analysis: June 6th, 2025 - The Globe and Mail
lucid capital markets initiates buy rating on cybin stock - Investing.com Australia
lucid capital markets initiates buy rating on cybin stock By Investing.com - Investing.com South Africa
Cybin (CYBN) Gains Positive Outlook from Lucid Capital | CYBN Stock News - GuruFocus
Cybin secures U.S. patent for program targeting generalized Anxiety disorder and depression - Proactive Investors
Cybin, Inc.The Strategic Approach to Formulating a Successful CYB003 Launch - Smartkarma
Massive News for DraftKings Stock Investors - The Globe and Mail
Psychedelic Drugs Market 2025 | Growth Trends, Mental Health - openPR.com
Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder - BioSpace
Cybin secures patent for anxiety disorder treatment CYB004 - Investing.com
Cybin Granted Additional US Patent for Potential Anxiety Disorder Treatments - MarketScreener
Cybin secures patent for anxiety disorder treatment CYB004 By Investing.com - Investing.com Canada
Cybin Secures U.S. Patent for CYB004 Program in Anxiety Disorder Treatment - TipRanks
Cybin (CYBN) Secures U.S. Patent for CYB004 Program | CYBN Stock News - GuruFocus
Cybin Announces Additional U.S. Patent Supporting its CYB004 Pro - GuruFocus
Will Blue Chip UPS Deliver for Shareholders? - The Globe and Mail
Cybin taps Thermo Fisher for U.S. manufacturing of CYB003 - MSN
Transcript : Cybin Inc.Special Call - marketscreener.com
(CYBN) Proactive Strategies - news.stocktradersdaily.com
Prediction: Dogecoin Will Plummet to New Lows by the End of the Year. Here's Why. - The Globe and Mail
Cboe Canada Single Security - Cboe Global Markets
Billionaire CEO Jamie Dimon Just Delivered a Stark Warning to the Market. Here Are 3 Things Investors Should Do. - The Globe and Mail
This Chinese Robotaxi Stock Could Be an Even Better Buy Than Tesla Before June - The Globe and Mail
Cybin CEO to Discuss Strategic Advances at Upcoming Fireside Chat - TipRanks
Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025 - BioSpace
Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025 | CYBN Stock News - GuruFocus
Cybin CEO Reveals Latest on Phase 3 Psychedelics Program and FDA Developments in Exclusive Analyst Chat - Stock Titan
Cybin Inc (CYBN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
0.42%
자본화:
|
볼륨(24시간):